Pravastatin Reduces the Risk of Atherothrombotic Stroke when Administered within Six Months of an Initial Stroke Event
Naohisa Hosomi, Yoji Nagai, Kazuo Kitagawa, Yoko Nakagawa, Shiro Aoki, Tomohisa Nezu, Tatsuo Kagimura, Hirofumi Maruyama, Hideki Origasa, Kazuo Minematsu, Shinichiro Uchiyama, Masayasu Matsumoto, J-STARS collaborators, Naohisa Hosomi, Yoji Nagai, Kazuo Kitagawa, Yoko Nakagawa, Shiro Aoki, Tomohisa Nezu, Tatsuo Kagimura, Hirofumi Maruyama, Hideki Origasa, Kazuo Minematsu, Shinichiro Uchiyama, Masayasu Matsumoto, J-STARS collaborators
Abstract
Aims: The J-STARS study examined whether pravastatin (10 mg/day) reduces recurrence of stroke in non-cardioembolic ischemic stroke patients who were enrolled within 1 month to 3 years after initial stroke events (ClinicalTrials.gov, NCT00221104). The main results showed that the frequency of atherothrombotic stroke was low in pravastatin-treated patients, although no effect of pravastatin was found for the other stroke subtypes. We evaluated differences of early (within 6 months) or late (after 6 months) pravastatin treatment benefits on the incidence of stroke or transient ischemic attack (TIA), as well as atherothrombotic stroke and the other subtypes.
Methods: Subjects in the J-STARS study were classified into two cohorts, depending on whether they enrolled early (1 to 6 months) or late (6 months to 3 years) following initial stroke events.
Results: A total of 1578 patients (491 female, 66.2±8.5 years) were randomly assigned to either the pravastatin group (n=793; n=426 in the early cohort, n=367 in the late cohort) or the control group (n=785; n=417 in the early cohort, n=368 in the late cohort). During the follow-up of 4.9± 1.4 years, the rate of atherothrombotic stroke was lower in the pravastatin group compared to controls in the early cohort (0.24 vs. 0.88%/year, p=0.01) but not in the late cohort (0.17 vs. 0.39%/year, p=0.29). However, this difference of pravastatin effect on atherothrombotic stroke was not significantly interacted by the early or late cohort (p=0.59). The incidence rates of other stroke subtype were not different in between pravastatin and control groups despite the timing of entry.
Conclusions: Pravastatin is likely to reduce atherothrombotic stroke in patients enrolled within 6 months after stroke onset. However, the clinical efficacy for prevention of recurrent stroke was not conclusive with earlier statin treatment.
Keywords: Atherothrombotic; Cholesterol; Prevention; Statin; Stroke.
Figures
References
- Zhong C, Xia W, Zhong X, Xu T, Li H, Zhang M, Wang A, Xu T, Sun Y, Zhang Y: Lipid Accumulation Product and Hypertension Related to Stroke: a 9.2-Year Prospective Study Among Mongolians in China. J Atheroscler Thromb, 2016; 23: 830-838
- Matsushima H, Hosomi N, Hara N, Yoshimoto T, Neshige S, Kono R, Himeno T, Takeshima S, Takamatsu K, Shimoe Y, Ota T, Maruyama H, Ohtsuki T, Kuriyama M, Matsumoto M: Ability of the Ankle Brachial Index and Brachial-Ankle Pulse Wave Velocity to Predict the 3-Month Outcome in Patients with Non-Cardioembolic Stroke. J Atheroscler Thromb, 2017; in press:
- Morris DR, Ayabe K, Inoue T, Sakai N, Bulbulia R, Halliday A, Goto S: Evidence-Based Carotid Interventions for Stroke Prevention: State-of-the-art Review. J Atheroscler Thromb, 2017; 24: 373-387
- Tada H, Kawashiri MA, Nohara A, Inazu A, Kobayashi J, Yasuda K, Mabuchi H, Yamagishi M, Hayashi K: Lipid Management in a Japanese Community: Attainment Rate of Target Set by the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012. J Atheroscler Thromb, 2017; 24: 338-345
- Usui T, Nagata M, Hata J, Mukai N, Hirakawa Y, Yoshida D, Kishimoto H, Kitazono T, Kiyohara Y, Ninomiya T: Serum Non-High-Density Lipoprotein Cholesterol and Risk of Cardiovascular Disease in Community Dwellers with Chronic Kidney Disease: the Hisayama Study. J Atheroscler Thromb, 2017; 24: 706-715
- Hosomi N, Nagai Y, Kohriyama T, Ohtsuki T, Aoki S, Nezu T, Maruyama H, Sunami N, Yokota C, Kitagawa K, Terayama Y, Takagi M, Ibayashi S, Nakamura M, Origasa H, Fukushima M, Mori E, Minematsu K, Uchiyama S, Shinohara Y, Yamaguchi T, Matsumoto M, collaborators JS : The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A multicenter, randomized, open-label, parallel-group study. EBioMedicine, 2015; 2: 1071-1078
- Amarenco P, Bogousslavsky J, Callahan A, 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med, 2006; 355: 549-559
- Nagai Y, Kohriyama T, Origasa H, Minematsu K, Yokota C, Uchiyama S, Ibayashi S, Terayama Y, Takagi M, Kitagawa K, Nomura E, Hosomi N, Ohtsuki T, Yamawaki T, Matsubara Y, Nakamura M, Yamasaki Y, Mori E, Fukushima M, Kobayashi S, Shinohara Y, Yamaguchi T, Matsumoto M, Investigators J-S : Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: the Japan Statin Treatment Against Recurrent Stroke (JSTARS). Int J Stroke, 2014; 9: 232-239
- Nakamura M, Fukukawa T, Kitagawa K, Nagai Y, Hosomi N, Matsumoto M, Minematsu K, Uchiyama S, Miyamoto Y: ANNALS EXPRESS: Ten-year standardization of lipids and high-sensitivity C-reactive protein in a randomized controlled trial to assess effects of statins on secondary stroke prevention: Japan Statin Treatment Against Recurrent Stroke (J-STARS). Ann Clin Biochem, 2017; 4563217693651
- Kitagawa K, Hosomi N, Nagai Y, Kagimura T, Ohtsuki T, Origasa H, Minematsu K, Uchiyama S, Nakamura M, Matsumoto M: Reduction in high-sensitivity C-reactive protein levels in patients with ischemic stroke by statin treatment: Hs-CRP Sub-study in J-STARS. J Atheroscler Thromb, 2017; in press:
- Hata J, Tanizaki Y, Kiyohara Y, Kato I, Kubo M, Tanaka K, Okubo K, Nakamura H, Oishi Y, Ibayashi S, Iida M: Ten year recurrence after first ever stroke in a Japanese community: the Hisayama study. J Neurol Neurosurg Psychiatry, 2005; 76: 368-372
Source: PubMed